Bionxt Solutions has launched the final animal study needed to prepare for human testing of BNT23001, its sublingual version of cladribine, in people with multiple sclerosis (MS). The 15-day dosing optimization […]
The post BioNxt’s BNT23001 for MS enters final animal test before human trials appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com